Abstract:RNA interference (RNAi) provides researchers with a versatile means to modulate target gene expression. The major forms of RNAi molecules, genome-derived microRNAs (miRNAs) and exogenous small interfering RNAs (siRNAs), converge into RNA-induced silencing complexes to achieve posttranscriptional gene regulation. RNAi has proven to be an adaptable and powerful therapeutic strategy where advancements in chemistry and pharmaceutics continue to bring RNAi-based drugs into the clinic. With four siRNA medications already approved by the US Food and Drug Administration (FDA), several RNAi-based therapeutics continue to advance to clinical trials with functions that closely resemble their endogenous counterparts. Although intended to enhance stability and improve efficacy, chemical modifications may increase risk of off-target effects by altering RNA structure, folding, and biologic activity away from their natural equivalents. Novel technologies in development today seek to use intact cells to yield true biologic RNAi agents that better represent the structures, stabilities, activities, and safety profiles of natural RNA molecules. In this review, we provide an examination of the mechanisms of action of endogenous miRNAs and exogenous siRNAs, the physiologic and pharmacokinetic barriers to therapeutic RNA delivery, and a summary of the chemical modifications and delivery platforms in use. We overview the pharmacology of the four FDA-approved siRNA medications (patisiran, givosiran, lumasiran, and inclisiran) as well as five siRNAs and several miRNA-based therapeutics currently in clinical trials. Furthermore, we discuss the direct expression and stable carrier-based, in vivo production of novel biologic RNAi agents for research and development. SIGNIFICANCE STATEMENT In our review, we summarize the major concepts of RNA interference (RNAi), molecular mechanisms, and current state and challenges of RNAi drug development. We focus our discussion on the pharmacology of US Food and Drug Administration-approved RNAi medications and those siRNAs and miRNA-based therapeutics that entered the clinical investigations. Novel approaches to producing new true biological RNAi molecules for research and development are highlighted.

Small Molecule Modifiers of the microRNA and RNA Interference Pathway

A Small Molecule Enhances RNA Interference and Promotes Microrna Processing

Small Molecules Modulating Biogenesis or Processing of microRNAs with Therapeutic Potentials

Small-Molecule Regulators of MicroRNAs in Biomedicine.

Novel approaches in cancer treatment: preclinical and clinical development of small non-coding RNA therapeutics

Small Molecules with Big Roles in Microrna Chemical Biology and Microrna-Targeted Therapeutics

Small interfering RNA for experimental cancer therapy.

Small molecules targeting microRNAs: new opportunities and challenges in precision cancer therapy

RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies

MicroRNA therapeutics: towards a new era for the management of cancer and other diseases

Effective tools for RNA-derived therapeutics: siRNA interference or miRNA mimicry

RNA Interference: From Basic Research to Therapeutic Applications

Heterobifunctional small molecules to modulate RNA function

Chemical Modification and Delivery System of Small Interfering RNA Drugs

De-Novo Design of pre-miR-21 Maturation Inhibitors: Synthesis and Activity Assessment

RNA Interference and Potential Applications

Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application

RNA Interference-Induced Innate Immunity, Off-Target Effect, or Immune Adjuvant?

Small molecule approaches to targeting RNA

siRNA, miRNA, and shRNA: in vivo Applications

Application of RNA Interference in Mammalian Cells